Medicare Drug Price Debate May Reemerge After Election, BIO Fears
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech association is comfortable with both presidential candidates, but concerned that they appear to support a heavier government hand in the Part D benefit.
You may also be interested in...
Waxman Plans Bill To Set Medicare Part D Drug Prices At Medicaid Level For Dual-eligibles
Bill comes on heels of House Oversight Committee report showing Part D plans pay on average 30 percent more for drugs compared to Medicaid.
Part D Success Enhances Pharma’s Political Effectiveness, Execs Predict
Industry gained enhanced bargaining position and improved image - advantages in future health care reform debates, Merck’s Clark and Schering-Plough’s Hassan say.
Senate Blocks Medicare Drug Price Negotiation Bill From Floor Vote
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.